China's Zai Lab hits 3-month peak as NMPA approves lung cancer drug
** Shares of Chinese biopharmaceutical group Zai Lab Ltd 9688.HK jump as much as 11% to HK$17.98, their highest since Feb. 2, and on course for fourth consecutive session of gains
** Zai Lab says China's National Medical Products Administration NMPA has approved the New Drug Application for its AUGTYROTM, or repotrectinib, for treatment of adult patients with metastatic ROS1-positive non-small-cell lung cancer
** Company says it has an exclusive license agreement with Turning Point Therapeutics Inc - a unit of Bristol Myers Squibb BMY.N, to develop and commercialize repotrectinib in mainland China, Hong Kong, Macau and Taiwan
** Hong Kong's healthcare index .HSCIH slips 0.7%, while Hang Seng Composite Index .HSCI climbs 0.7% and Hang Seng Index .HSI adds 0.5%
** Zai Lab stock down 23.8% YTD
Reporting by Donny Kwok
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
